Aspen Neuroscience announced the publication in Cell Stem Cell of a peer-reviewed paper describing the preclinical evaluation and genomic quality controls for Sasineprocel (ANPD001), its autologous iPSC-derived dopamine neuron replacement therapy for Parkinson’s disease.
The paper, the company claims, documents reproducible characterization and manufacturing of dopaminergic neuron precursor cells across multiple cell lines and presents NeuriTest, a proprietary RNA sequencing-based bioinformatics assay that uses machine learning to evaluate molecular identity and predicted performance of patient-specific products.
According to the company, preclinical studies showed improvement in motor function in Parkinson’s models and no treatment-related adverse findings in a nine-month GLP rodent safety study, data the company claims supported advancement into the ongoing Phase 1/2a ASPIRO clinical trial and aligns with the company entering Phase 3.
Sasineprocel is a single-dose autologous therapy produced from a patient’s skin biopsy, delivered to the putamen and intended to replace lost dopaminergic neurons without requiring immunosuppression.
